{"id":1063294,"date":"2010-05-02T08:16:53","date_gmt":"2010-05-02T08:16:53","guid":{"rendered":"http:\/\/www.longevitymedicine.tv\/more-about-presentations-at-aacr10\/"},"modified":"2024-08-17T20:28:29","modified_gmt":"2024-08-18T00:28:29","slug":"more-about-presentations-at-aacr10","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/more-about-presentations-at-aacr10.php","title":{"rendered":"More about presentations at AACR10"},"content":{"rendered":"<p>Five presentations  at the <a title=\"101th annual meeting\" href=\"http:\/\/www.aacr.org\/home\/scientists\/meetings--workshops\/aacr-101st-annual-meeting-2010.aspx\" target=\"_blank\" rel=\"noopener\">101th annual meeting<\/a> of the <a title=\"American Association of Cancer Research\" href=\"http:\/\/www.aacr.org\/default.aspx\" target=\"_blank\" rel=\"noopener\">American Association of Cancer Research<\/a> were highlighted  a <a title=\"news release\" href=\"http:\/\/www.geron.com\/media\/pressview.aspx?id=1216\" target=\"_blank\" rel=\"noopener\">news release<\/a> from <a title=\"Geron\" href=\"http:\/\/www.geron.com\/\" target=\"_blank\" rel=\"noopener\">Geron<\/a> Corporation (dated March 3, 2010). One presentation that had an explicit focus on CSC was this poster:<\/p><p><em>Imetelstat, a telomerase inhibitor in phase I trials in solid tumor and  hematological malignancies, has broad activity against multiple types of  cancer stem cells<\/em> [<a title=\"Presentation Abstract\" href=\"http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=c8503a5d-cbe1-43fd-9652-46df1acdf9dd&amp;cKey=e30934bc-79fc-4728-986f-21b7886aaaeb&amp;mKey=%7B0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7D\" target=\"_blank\" rel=\"noopener\">Presentation Abstract<\/a>].<\/p><p>Also mentioned in the <a title=\"news release\" href=\"http:\/\/www.geron.com\/media\/pressview.aspx?id=1216\" target=\"_blank\" rel=\"noopener\">news release<\/a> was an oral presentation by <a title=\"Jerry W Shay\" href=\"http:\/\/www.utsouthwestern.edu\/findfac\/professional\/0,,16566,00.html\" target=\"_blank\" rel=\"noopener\">Jerry W Shay<\/a>, given as part of the Major  Symposium entitled: <em>Role of Telomeres and Telomerase in Chromosomal Stability and  Disease<\/em> [<a title=\"Session Detail\" href=\"http:\/\/www.abstractsonline.com\/Plan\/ViewSession.aspx?mID=1668&amp;sKey=2fc55ca3-cfff-496d-9367-4be60313dc89&amp;mKey=%7B0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7D\" target=\"_blank\" rel=\"noopener\">Session Detail<\/a>]. The presentation was:<\/p><p><em>Role of telomerase in normal and neoplastic stem cells<\/em> [<a title=\"Presentation Abstract\" href=\"http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=2fc55ca3-cfff-496d-9367-4be60313dc89&amp;cKey=eb033824-9b69-4970-a164-47b6908ddd55&amp;mKey=%7B0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7D\" target=\"_blank\" rel=\"noopener\">Presentation Abstract<\/a>].<\/p><p>Another poster about the telomerase inhibitor imetelstat (GRN163L) was:<\/p><p><em>Sensitivity and resistance of non-small cell lung cancer to the  telomerase inhibitor imetelstat<\/em> [<a title=\"Presentation Abstract\" href=\"http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=2672bc39-b998-4568-aa4f-c91cc83ede8e&amp;cKey=59a50406-98f3-4874-a484-2106ac20b5cb&amp;mKey=%7B0591FA3B-AFEF-49D2-8E65-55F41EE8117E%7D\" target=\"_blank\" rel=\"noopener\">Presentation Abstract<\/a>].<\/p><p><span>Comments<\/span>: A search of the <a title=\"ClinicalTrials.gov\" href=\"http:\/\/clinicaltrials.gov\/ct2\/home\" target=\"_blank\" rel=\"noopener\">ClinicalTrials.gov<\/a> database for <a title=\"GRN163L\" href=\"http:\/\/clinicaltrials.gov\/ct2\/results?term=&amp;recr=&amp;rslt=&amp;type=&amp;cond=&amp;intr=GRN163L&amp;outc=&amp;lead=&amp;spons=&amp;id=&amp;state1=&amp;cntry1=&amp;state2=&amp;cntry2=&amp;state3=&amp;cntry3=&amp;locn=&amp;gndr=&amp;rcv_s=&amp;rcv_e=&amp;lup_s=&amp;lup_e=\" target=\"_blank\" rel=\"noopener\">GRN163L<\/a> revealed 6  trials. Four were ongoing, but not recruiting participants. Two were still recruiting: 1) <a title=\"Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies\" href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00310895\" target=\"_blank\" rel=\"noopener\">Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies<\/a>; 2) <a title=\"Show study NCT00732056: A Study of GRN163L With Paclitaxel and  Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic  Breast Cancer\" href=\"http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00732056\" target=\"_blank\" rel=\"noopener\">A  Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With  Locally Recurrent Or Metastatic Breast Cancer<\/a>.<\/p><p>An analogous search for <a title=\"imetelstat\" href=\"http:\/\/clinicaltrials.gov\/ct2\/results?term=&amp;recr=&amp;rslt=&amp;type=&amp;cond=&amp;intr=imetelstat&amp;outc=&amp;lead=&amp;spons=&amp;id=&amp;state1=&amp;cntry1=&amp;state2=&amp;cntry2=&amp;state3=&amp;cntry3=&amp;locn=&amp;gndr=&amp;rcv_s=&amp;rcv_e=&amp;lup_s=&amp;lup_e=\" target=\"_blank\" rel=\"noopener\">imetelstat<\/a> yielded the same 6 trials. All 6 trials have been sponsored by <a title=\"Geron\" href=\"http:\/\/www.geron.com\/\" target=\"_blank\" rel=\"noopener\">Geron<\/a>  Corporation.<\/p><div><img loading=\"lazy\" decoding=\"async\" width=\"1\" height=\"1\" src=\"http:\/\/www.longevitymedicine.tv\/wp-content\/plugins\/wp-o-matic\/cache\/84e3e_35997458635844014-8014061296420712982?l=cancerstemcellnews.blogspot.com\" alt=\"\" style=\"padding-left:10px; padding-right: 10px;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>Five presentations at the 101th annual meeting of the American Association of Cancer Research were highlighted a news release from Geron Corporation (dated March 3, 2010). One presentation that had an explicit focus on CSC was this poster:Imetelstat, a telomerase &hellip; <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/more-about-presentations-at-aacr10.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25,1246878],"tags":[],"class_list":["post-1063294","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy","category-stem-cells"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063294"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1063294"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1063294\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1063294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1063294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1063294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}